NanoTemper Technologies Establishes Advisory Board to Propel Innovation and Growth
Munich, Germany, July 12, 2024 – NanoTemper Technologies is proud to announce a significant milestone in its journey toward excellence and innovation in the biotech industry. The company has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper Technologies’ commitment to fostering cutting-edge development while staying true to its mission – to create a world where every disease is treatable.
The members of the newly formed advisory board are:
- Bettina Berendsen | Senior Associate Advisor, e&Co. Life Sciences
- Oliver Klaeffling | Managing Director, Analytik Jena
- Hanns-Christian Mahler | CEO, ten23 health
- Michael Pohlscheidt | EVP & COO, Jungbunzlauer
- Nikolai Ahrens | Founder, LifeScience ORG
“The establishment of our advisory board marks a pivotal moment for NanoTemper Technologies,” says Philipp Baaske, co-Founder and CEO of NanoTemper Technologies. “Their wealth of knowledge and experience will significantly enhance our efforts in driving innovation and maintaining the highest standards of excellence in the biotech industry. We are confident that their contributions will help us grow even stronger, uphold our principles, and directly contribute to our dynamic team.”
The advisory board will not only provide high-level guidance but will also engage directly with NanoTemper Technologies’ teams. This collaborative approach aims to create an environment where innovation flourishes, benefiting from the direct involvement and insights of these industry leaders.
Please join us in welcoming our new advisory board members. We look forward to the invaluable guidance and innovative perspectives they will bring to NanoTemper Technologies.
About NanoTemper Technologies
At NanoTemper, our vision is to help create a world where every disease is treatable. For us, that starts by equipping scientists with reliable biophysical tools that bring them the clarity, confidence, and momentum they need to discover and develop future therapies, even difficult ones. Because the path to a disease-free world requires courage, big thinking, and collaboration, we’ll continue to create innovative products that meet the needs of our customers as they face new and difficult challenges.